Featured 13F manager
Merck & Co., Inc.
Rahway, NJ 4 processed 13Fs on this site · 2025 Q3–2026 Q2
- $526M
- 13 Positions
- 2026 Q2
- +50.7% QoQ
- Top 5 93.3%
Merck & Co., Inc. files a Form 13F. The latest book is 2026 Q2 at $526M, up 50.7% QoQ, led by Personalis, Moderna, and Kymera Therapeutics.
Portfolio
top 5 93.3% · top 10 99.8%
- PSNL - Personalis 35.8%
- MRNA - Moderna 30.7%
- KYMR - Kymera Therapeutics 16.8%
- AKTS - Aktis Oncology 5.9%
- EIKN - Eikon Therapeutics 4.1%
- TRDA - Entrada Therapeutics 2.4%
- STRO - Sutro Biopharma 1.7%
- ALEC - Alector 1.4%
- Evaxion Biotech A/S 0.7%
- Viridian Therapeutics 0.3%
- Xilio Therapeutics 0.2%
- Tuhura Biosciences 0.0%
- Other 0.0%
AUM over time
Book
| PSNL - Personalis | 40.16% | Hold | 14,044,943 | $6.52 | $92M |
| MRNA - Moderna | 26.15% | Hold | 2,308,190 | $25.83 | $60M |
| KYMR - Kymera Therapeutics | 19.17% | Hold | 772,165 | $56.60 | $44M |
| ALEC - Alector | 4.60% | Hold | 3,545,719 | $2.96 | $10M |
| TRDA - Entrada Therapeutics | 4.43% | Hold | 1,739,768 | $5.80 | $10M |
| Evaxion Biotech A/S | 2.00% | Hold | 1,214,126 | $3.76 | $5M |
| Sutro Biopharma | 1.04% | Hold | 2,723,509 | $0.8684 | $2M |
| Viridian Therapeutics | 0.88% | Hold | 93,414 | $21.58 | $2M |
| Lava Therapeutics | 0.79% | Hold | 1,149,345 | $1.56 | $2M |
| Xilio Therapeutics | 0.55% | Hold | 1,483,758 | $0.8427 | $1M |
| Carisma Therapeutics | 0.18% | Hold | 1,473,240 | $0.2740 | $404K |
| Neuphoria Therapeutics | 0.05% | Hold | 10,027 | $11.79 | $118K |
| Tuhura Biosciences | 0.02% | Hold | 13,950 | $2.48 | $35K |
Filings history
4 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 13 | $526M | +50.7% | 13F-HR | 8/7/2026 | 000031015826000210 |
| 2026 Q1 | 14 | $349M | +26.4% | 13F-HR | 5/13/2026 | 000031015826000141 |
| 2025 Q4 | 12 | $276M | +21.1% | 13F-HR | 2/17/2026 | 000031015826000055 |
| 2025 Q3 | 13 | $228M | — | 13F-HR | 11/12/2025 | 000031015825000063 |
About
Merck & Co., Inc.
4 processed 13Fs on this site · 2025 Q3–2026 Q2